natgillin/translations-raw huggingface dataset:
Always use the oral syringe provided to take your medicine. 
Za jemanje zdravila vedno uporabite priloženo odmerno brizgo.
Caution should be exercised in the treatment of patients, adult and children above 6 years of age, with renal impairment and the dose should be adjusted according to creatinine clearance (CLCR) as follows: - CLCR >60 ml/min: no dose adjustment required. 
Pri zdravljenju bolnikov, odraslih in otrok, starih več kot 6 let, z ledvično okvaro je potrebna previdnost, odmerek pa je treba prilagoditi glede na kreatininski očistek (CLCR) na naslednji način: - CLCR > 60 ml/min: prilagajanje odmerka ni potrebno;
• Abnormal sense of touch; 
• pekoč občutek, • nenormalen občutek za dotik,
The safety of Zebinix in children aged 6 years and below has not yet been established. 
Varnost zdravila Zebinix pri otrocih, starih 6 let ali manj, ni bila ugotovljena.
• Hair loss; 
• izguba las,
There was no effect on the Rwarfarin pharmacokinetics or on coagulation. 
Učinka na farmakokinetiko R-varfarina ali na koagulacijo ni bilo.
What you need to know before you take Zebinix Do not take Zebinix: 
Kaj morate vedeti, preden boste vzeli zdravilo Zebinix Ne jemljite zdravila Zebinix:
• Feeling extremely sleepy; 
• izjemna zaspanost,
If you are taking Zebinix on its own your doctor may consider you can benefit of a dose of 1,600 mg once daily. 
Če zdravilo Zebinix jemljete samostojno, bo zdravnik morda presodil, da bo korist večja pri odmerku 1.600 mg enkrat na dan.
(increase of ≥25%) compared to Baseline Parts III-V was 25.7%. 
≥ 25 %) v primerjavi z izhodiščno vrednostjo delov III do V je bil 25,7 %.
Amongst these, when excluding patients aged 6 years and younger, 14 (48.3%) and 11 (30.6%) of patients in the eslicarbazepine acetate and placebo group, respectively, were responders (p=0.1514). 
Med njimi je bilo po izključitvi bolnikov, starih 6 let ali manj, odzivnih 14 (48,3 %) in 11 (30,6 %) v skupini z eslikarbazepinacetatom oz. v skupini s placebom (p = 0,1514).
Eslicarbazepine acetate was tested at doses of 20 and 30 mg/kg/day, up to a maximum of 1,200 mg/day. 
Eslikarbazepinacetat so testirali v odmerku 20 in 30 mg/kg/dan, do največ 1.200 mg/dan.
Ask your doctor or pharmacist. 
Posvetujte se z zdravnikom ali farmacevtom.
Zebinix is for oral use. 
Zdravilo Zebinix je za peroralno uporabo.
• Urticaria (skin rash with itching). 
• urtikarija (koprivnica; srbeč kožni izpuščaj).
Symptoms include tremors, pain, cramping; 
Simptomi vključujejo tresenje, bolečine in krče,
• Mood changes or hallucinations; 
• spremembe razpoloženja ali blodnje,
Seizure-free rates during the entire 10-week monotherapy period were 7.6% (1,600 mg) and 8.3 % (1,200 mg) in one study and 10.0% (1,600 mg) and 7.4 % (1,200 mg) in the other study, respectively. 
Eslikarbazepinacetat so preskušali v odmerkih 1.200 mg in 1.600 mg z odmerjanjem enkrat na dan. Deleži preskušancev brez napadov v celotnem 10-tedenskem obdobju monoterapije so bili 7,6 % (1.600 mg) in 8,3 % (1.200 mg) v eni študiji ter 10,0 % (1.600 mg) in 7,4 % (1.200 mg) v drugi študiji.
There are no data on the effects of eslicarbazepine acetate on human fertility. 
Podatkov o učinkih eslikarbazepinacetata na plodnost pri ljudeh ni.
Of these, 65 patients had received ESL and 87 patients had received placebo during the double-blind part of the study. 
del študije, je bilo 152 bolnikov vključenih v III. del. Od teh je 65 bolnikov prejemalo eslikarbazepinacetat in 87 bolnikov placebo v dvojno slepem delu študije.
The maximum dose is 1,200 mg once daily. 
Največji odmerek je 1.200 mg enkrat na dan.
Eslicarbazepine acetate was not teratogenic in the rat or rabbit, but did induce skeletal abnormalities in the mouse. 
Eslikarbazepinacetat ni bil teratogen pri podganah ali kuncih, a je pri miših izzval nenormalnosti okostja.
The adverse reaction profile of eslicarbazepine acetate is generally similar across age goups. 
Profil neželenih učinkov eslikarbazepinacetata je na splošno podoben v vseh starostnih skupinah.
• Blood tests showing that you have low levels of sodium in your blood; 
• krvne preiskave, ki kažejo nizke ravni natrija v krvi,
In clinical studies (adjunctive therapy treatment and monotherapy), 2,434 patients with partial-onset seizures were treated with eslicarbazepine acetate (1,983 adult patients and 451 paediatric patients) and 51% of those patients experienced adverse reactions. 
V kliničnih študijah (dodatno zdravljenje in monoterapija) so z eslikarbazepinacetatom zdravili 2.434 bolnikov s parcialnimi epileptičnimi napadi (1.983 odraslih bolnikov in 451 pediatričnih bolnikov), od katerih je 51 % imelo neželene učinke.
400 mg once daily for one or two weeks, before increasing to the maintenance dose. 
400 mg enkrat na dan en ali dva tedna, nato se odmerek zveča na vzdrževalni odmerek.
Eslicarbazepine acetate adversely interacts with oral contraceptives. 
Eslikarbazepinacetat ima neželeno medsebojno delovanje s peroralnimi kontraceptivi.
• adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation. 
• dodatno zdravljenje pri odraslih, mladostnikih in otrocih, starih več kot 6 let, s parcialnimi epileptičnimi napadi s sekundarno generalizacijo ali brez nje.
HLA-B* 1502 in individuals of Han Chinese and Thai origin has been shown to be strongly associated with the risk of developing the severe cutaneous reactions known as Stevens Johnson syndrome (SJS) when treated with carbamazepine. 
Pokazalo se je, da je prisotnost HLA-B* 1502 pri posameznikih Han kitajske ali tajske narodnosti, ki prejemajo karbamazepin, tesno povezana s tveganjem za razvoj hudih kožnih reakcij, znanih kot Stevens-Johnsonov sindrom (SJS).
There are some data that suggest HLA-A*3101 is associated with an increased risk of carbamazepine induced cutaneous adverse drug reactions including SJS, TEN, Drug rash with eosinophilia (DRESS), or less severe acute generalized exanthematous pustulosis (AGEP) and maculopapular rash in people of European descent and the Japanese. 
Nekateri podatki nakazujejo, da je HLA-A*3101 povezan z večjim tveganjem kožnih neželenih učinkov, ki jih povzroči karbamazepin, vključno s Stevens-Johnsonovim sindromom (SJS), toksično epidermalno nekrolizo (TEN), izpuščajem zaradi zdravila z eozinofilijo ali manj hudo akutno generalizirano eksantematozno pustulozo in makulopapularnim izpuščajem pri populacijah evropskega porekla in japonske narodnosti.
The total median standardised seizure frequency was 6.1 (decreasing from 7.0 (weeks 1-4) to 4.0 (weeks > 40), resulting in a median relative change compared to the baseline period of -46.7%). 
Skupna mediana standardizirana pogostnost epileptičnih napadov je bila 6,1 (ki se je znižala s 7,0 (1.-4. teden) na 4,0 (> 40. teden), kar pomeni mediano relativno spremembo
Zebinix tablets may be taken with or without food. 
Tablete Zebinix lahko jemljete s hrano ali brez nje.
• simvastatin (a medicine used to lower cholesterol levels) since your dose may have to be adjusted; 
• simvastatin (zdravilo za zniževanje koncentracije holesterola v krvi), kajti morda bo treba prilagoditi odmerek;
What Zebinix is and what it is used for 
Kaj je zdravilo Zebinix in za kaj ga uporabljamo
Population pharmacokinetics indicate that comparable eslicarbazepine exposure is observed between 20 and 30 mg/kg/day in children above 6 years old and adults with 800 and 1200 mg of eslicarbazepine acetate once-daily, respectively (see section 4.2). 
Populacijska farmakokinetika kaže, da so primerljivo izpostavljenost eslikarbazepinu opazili pri odmerkih eslikarbazepinacetata med 20 in 30 mg/kg/dan pri otrocih, starih več kot 6 let, ter pri 800 mg in 1200 mg enkrat dnevno pri odraslih (glejte poglavje 4.2).
If you forget to take Zebinix 
Če ste pozabili vzeti zdravilo Zebinix
The efficacy of eslicarbazepine acetate as adjunctive therapy has been demonstrated in four phase III double-blind placebo-controlled studies in 1,703 randomized adult patients with partial epilepsy refractory to treatment with one to three concomitant antiepileptic medicinal products. 
Učinkovitost eslikarbazepinacetata kot dodatno zdravljenje so pokazali v štirih dvojno slepih, s placebom nadzorovanih študijah III. faze pri 1.703 randomiziranih odraslih bolnikih s parcialno epilepsijo, ki se odziva na zdravljenje z enim do tremi antiepileptiki.
3 years. 
2 leti
In placebo-controlled studies involving patients aged from 2 to 18 years with partial-onset seizures (238 patients treated with eslicarbazepine acetate and 189 with placebo), 35.7% of patients treated with eslicarbazepine acetate and 19% of patients treated with placebo experienced adverse reactions. 
V študijah, nadzorovanih s placebom, v katere so bili vključeni bolniki, stari od 2 do 18 let s parcialnimi napadi (238 bolnikov, zdravljenih z eslikarbazepinacetatom, in 189 s placebom), je 35,7 % bolnikov, zdravljenih z eslikarbazepinacetatom, in 19 % bolnikov, zdravljenih s placebom,
If you accidently take more Zebinix than you should, you are potentially at risk of having more seizures; or you may feel like your heart beat is irregular or faster. 
Če po nesreči vzamete več zdravila Zebinix, kot bi smeli, se pri vas lahko poveča število epileptičnih napadov ali pa boste morda čutili, da je vaš srčni utrip nereden ali hitrejši.
7 tablets 14 tablets 28 tablets 
7 tablet 14 tablet 28 tablet
Impairment of fertility was observed in female rats; decreases in implantations and live embryos seen in the mouse fertility study may also indicate effects on female fertility, however, corpora lutea counts were not evaluated. 
Pri podganjih samicah so opazili vpliv na plodnost; zmanjšanje implantacij in živih embrijev so opazili v študiji plodnosti pri miših, kar lahko kaže tudi na učinek na plodnost pri ženskah, vendar števila rumenih telesc niso ocenjevali.
Study 208 included 2 additional subsequent long-term, open-label extensions (1 year in part II and 2 years in part III) and Study 305 included 4 subsequent long-term, open-label extension periods (1 year in Parts II, III and IV and 2 years in Part V). 
delu in 2 leti v III. delu) in študija 305 je zajemala 4 poznejša dolgotrajna nezaslepljena podaljšana obdobja (1 leto v II., III. in IV. delu ter 2 leti v V. delu).
Two clusters of ADRs were identified in context of overdose cases - epilepsy/seizures/status epilepticus and cardiac events, mainly arrhythmias. 
Na podlagi primerov prevelikega odmerjanja so ugotovili dve skupini neželenih učinkov zdravila, in sicer epilepsijo/epileptične napade/epileptični status in srčne dogodke, večinoma aritmije.
The most common adverse reactions reported, in placebo controlled adjunctive therapy studies with adult epileptic patients and in an active controlled monotherapy study comparing eslicarbazepine acetate with carbamazepine controlled release, were dizziness, somnolence, headache, and nausea. 
Najpogostejši neželeni učinki, o katerih so poročali v s placebom kontroliranih študijah dodatnega zdravljenja pri odraslih bolnikih z epilepsijo in v z aktivnim zdravilom kontrolirani študiji monoterapije, kjer so primerjali eslikarbazepinacetat s karbamazepinom z nadzorovanim sproščanjem, so bili omotica, zaspanost, glavobol in navzea.
Take special care with Zebinix: 
Pri zdravilu Zebinix bodite posebno previdni:
Eslicarbazepine acetate has been associated with some central nervous system adverse reactions, such as dizziness and somnolence, which could increase the occurrence of accidental injury. 
Uporaba eslikarbazepinacetata je povezana z nekaterimi neželenimi učinki v osrednjem živčevju, kot sta omotica in somnolenca, ki lahko povečajo pogostnost nezgodnih poškodb.
Zebinix is not recommended in patients with severe renal disease. 
Zebinix ni priporočeno pri bolnikih s hudo ledvično boleznijo.
Therefore, women of childbearing potential must use adequate contraception during treatment with Zebinix, and up to the end of the current menstruation cycle after the treatment has been discontinued (see section 4.6). 
Zato morajo ženske v rodni dobi med zdravljenjem z zdravilom Zebinix in do konca trenutnega menstrualnega cikla po prekinitvi zdravljenja uporabljati ustrezno kontracepcijo (glejte poglavje 4.6).
As a risk to the breast-fed child cannot be excluded breastfeeding should be discontinued during treatment with eslicarbazepine acetate. 
Tveganja za dojenčka ni mogoče izključiti, zato je treba med zdravljenjem z eslikarbazepinacetatom dojenje prekiniti.
As clinical data are limited in patients with mild to moderate hepatic impairment and pharmacokinetic and clinical data are missing in patients with severe hepatic impairment, eslicarbazepine acetate should be used with caution in patients with mild to moderate hepatic impairment and is not recommended in patients with severe hepatic impairment. 
Pri bolnikih z blago do zmerno jetrno okvaro je kliničnih podatkov malo, pri bolnikih s hudo jetrno okvaro pa farmakokinetičnih in kliničnih podatkov ni, zato je treba pri bolnikih z blago do zmerno jetrno okvaro eslikarbazepinacetat uporabljati previdno, pri bolnikih s hudo jetrno okvaro pa njegova uporaba ni priporočena.
Taking into account the PRAC Assessment Report on the PSUR(s) for eslicarbazepine acetate, the scientific conclusions of CHMP are as follows: 
Upoštevajoč poročilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) o oceni redno posodobljenih poročil o varnosti zdravila (PSUR) za eslikarbazepinacetat je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel naslednje znanstvene zaključke:
If clinically-relevant hyponatraemia develops, eslicarbazepine acetate should be discontinued. 
Če se pojavi klinično pomembna hiponatriemija, je treba uporabo eslikarbazepinacetata prekiniti.
Blood pressure decreased, weight decreased, blood pressure increased, blood sodium decreased, blood chloride decreased, osteocalcin increased, haematocrit decreased, haemoglobin decreased, transaminases increased 
Preiskave povečana telesna masa znižan krvni tlak, zmanjšana telesna masa, zvišan krvni tlak, znižan natrij v krvi, znižana raven kloridov v krvi, zvišana raven osteokalcina, znižan hematokrit, znižan hemoglobin, zvišane transaminaze
Glucuronidation is the major metabolic pathway for both eslicarbazepine and lamotrigine and therefore, an interaction could be expected. 
Glavna presnovna pot eslikarbazepina in lamotrigina je glukuronidacija, zato bi lahko pričakovali interakcije.
In the age group from 6 to 11 years of age, the most common adverse reaction observed in more than two patients treated with eslicarbazepine acetate were diplopia (9.5%), somnolence (7.4%), diziness (6.3%), convulsion (6.3%) and nausea (3.2%); in the age group from 12 to 18 years were somnolence (7.4%), vomiting (4.2%), diplopia (3.2%) and fatigue (3.2%). 
V starostni skupini od 6 do 11 let so bili najpogostejši neželeni učinki, ki so jih opazili pri več kot dveh bolnikih, zdravljenih z eslikarbazepinacetatom, diplopija (9,5 %), somnolenca (7,4 %), omotičnost (6,3 %), konvulzija (6,3 %) in navzea (3,2 %); v starostni skupini od 12 do 18 let pa somnolenca (7,4 %), bruhanje (4,2 %), diplopija (3,2 %) in utrujenost (3,2 %).
In the subsequent 1-year open-label extension (Part II) of the phase III study (ITT set N=225) the total responder rate was 46.7% (steadily increasing from 44.9% (weeks 1-4) to 57.5% (weeks > 40)). 
del) študije III. faze (nabor ITT N = 225) je bila skupna stopnja odziva 46,7 % (ki je enakomerno naraščala od 44,9 % (1.-4. teden) do 57,5 % (> 40. teden)).
What Zebinix looks like and contents of the pack 
Izgled zdravila Zebinix in vsebina pakiranja
Gently pull the plunger of the oral syringe to the desired volume. 
Nežno povlecite bat odmerne brizge do želene količine.
Zebinix contains methyl parahydroxybenzoate (E218) and sulphites 
Zdravilo Zebinix vsebuje metilparahidroksibenzoat (E218) in sulfite
Eslicarbazepine acetate metabolites are eliminated from the systemic circulation primarily by renal excretion, in the unchanged and glucuronide conjugate forms. 
Izločanje Presnovki eslikarbazepinacetata se izločajo iz sistemskega obtoka predvsem skozi ledvice, v nespremenjeni obliki in kot glukuronidni konjugat.
Based on individual response, the dose of eslicarbazepine acetate may need to be increased if used concomitantly with carbamazepine. 
Glede na odziv posameznega bolnika bo morda treba odmerek eslikarbazepinacetata povečati, kadar se ga uporablja sočasno z karbamazepinom.
In vitro eslicarbazepine is a weak inducer of CYP3A4 and UDP-glucuronyl transferases. 
Eslikarbazepin je in vitro šibek spodbujevalec encima CYP3A4 in UDPglukuroniltransferaz.
If you stop taking Zebinix 
Če ste prenehali jemati zdravilo Zebinix
Place the oral syringe into the mouth against the inside of the cheek. 
9. korak: Odmerno brizgo si dajte v usta proti notranjosti lic.
Depending on the response to Zebinix, the dose may be increased by 10 mg per kg body weight, at intervals of one or two weeks, up to 30 mg per kg body weight. 
Glede na odziv na zdravilo Zebinix se lahko odmerek povečuje po 10 mg na kg telesne mase v eno- ali dvotedenskih intervalih, do 30 mg na kg telesne mase.
The maximum dose is 1,200 mg once daily (see section 5.1). 
Največji odmerek je 1.200 mg enkrat dnevno (glejte poglavje 5.1).
200 ml bottle oral syringe (10 ml) (outer pack only) 
200-ml steklenica odmerna brizga (10 ml) (samo zunanja ovojnina)
However, based on individual response, the dose may be increased. 
Glede na odziv posameznika se odmerek lahko zveča do
Plasma levels of eslicarbazepine acetate usually remain below the limit of quantification, following oral administration. 
Ravni eslikarbazepinacetata v plazmi po peroralni uporabi običajno ostanejo pod ravnijo kvantifikacije.
• Tingling and/or feeling numb in any part of your body; 
• bolečina v prsnem košu, • občutek mravljinčenja in/ali otrplosti v katerem koli delu telesa,
• Disturbances in the sense of smell; 
• motnje vonja,
The proportion of patients with exacerbation (increase of ≥25%) compared to the baseline period was 14.2%. 
Delež bolnikov s poslabšanjem (povečanjem ≥ 25 %) v primerjavi z izhodiščem je bil
• if you have kidney problems. 
• če imate težave z ledvicami.
• if you have blistering or peeling of the skin and/or mucous membranes, rash, swallowing or breathing problems, swelling of your lips, face, eyelids, throat or tongue. 
• če imate mehurje ali luščenje kože in/ali sluznic, izpuščaj, težave pri požiranju ali dihanju in otekanje ustnic, obraza, vek, grla ali jezika.
A study in healthy subjects showed no effect of eslicarbazepine acetate 1,200 mg once daily on digoxin pharmacokinetics, suggesting that eslicarbazepine acetate has no effect on the transporter Pglycoprotein. 
Digoksin Študija pri zdravih osebah je pokazala, da uporaba 1.200 mg eslikarbazepinacetata enkrat na dan nima učinka na farmakokinetiko digoksina, kar kaže na to, da eslikarbazepinacetat nima učinka na transportni P-glikoprotein.
Zebinix oral suspension may be taken with or without food. 
Zdravilo Zebinix peroralna suspenzija lahko jemljete s hrano ali brez nje.
20 tablets 30 tablets 60 tablets 90 tablets 
20 tablet 30 tablet 60 tablet 90 tablet
Similar to adults, eslicarbazepine acetate is extensively converted to eslicarbazepine. 
Podobno kot pri odraslih se eslikarbazepinacetat obširno pretvori v eslikarbazepin.
Zebinix 50 mg/ml oral suspension 
Zebinix 50 mg/ml peroralna suspenzija
In children above 6 years, 36 patients (35.0%) in the eslicarbazepine acetate group compared to 29 patients (30.2%) in the placebo group were responders (p=0.4759) and the least square mean reduction in standardised seizure frequency was higher in the eslicarbazepine acetate group compared to placebo (-24.4% versus -10.5%); however, the difference of 13.9% was not statistically significant (p=0.1040). 
Pri otrocih, starih nad 6 let, je bilo odzivnih 36 bolnikov (35,0 %) v skupini z eslikarbazepinacetatom v primerjavi z 29 bolniki (30,2 %) v skupini s placebom (p = 0,4759), in povprečno zmanjšanje najmanjših kvadratov v standardizirani pogostnosti napadov je bilo večje v skupini z eslikarbazepinacetatom v primerjavi s placebom (-24,4 % v primerjavi z -10,5 %); vendar razlika 13,9 % ni bila statistično značilna (p = 0,1040).
The efficacy of eslicarbazepine acetate as monotherapy has been demonstrated in a double-blind, active controlled (carbamazepine controlled release) study, involving 815 randomized adult patients with newly diagnosed partial-onset seizures. 
Učinkovitost eslikarbazepinacetata kot monoterapije so dokazali v dvojno slepi, z aktivno učinkovino (karbamazepin z nadzorovanim sproščanjem) kontrolirani študiji, v katero je bilo zajetih 815 randomiziranih odraslih bolnikov z na novo diagnosticiranimi parcialnimi epileptičnimi napadi.
The total median standardised seizure frequency was 2.4 (resulting in a median relative change from Baseline Part III-V of -22.9%). 
Skupna mediana standardizirana pogostnost epileptičnih napadov je bila 2,4 (kar pomeni mediano relativno spremembo -22,9 % v primerjavi z izhodiščno vrednostjo delov III do V).
The use of Zebinix is associated with an abnormality in ECG (electrocardiogram) called increase in PR interval. 
Uporaba zdravila Zebinix je povezana z nenormalnim pojavom pri elektrokardiogramu (EKG),
• Weight increase. 
• povečanje telesne mase.
Zebinix may make hormonal contraceptives such as the contraceptive pill less effective. 
Hormonski kontraceptivi, kot so kontracepcijske tablete, so lahko zaradi zdravila Zebinix manj učinkovita.
The safety and efficacy of eslicarbazepine acetate as adjunctive therapy for partial seizures in elderly patients were evaluated in one non-controlled study, with a duration of 26 weeks, in 72 elderly (aged ≥ 65 years). 
Varnost in učinkovitost eslikarbazepinacetata kot dodatnega zdravljenja pri parcialnih epileptičnih napadih pri starejših bolnikih so ocenili v eni nenadzorovani študiji, ki je trajala 26 tednov, z
Zebinix is not recommended if you have severe kidney problems. 
Uporaba zdravila Zebinix ni priporočena, če imate hude težave z ledvicami.
In vivo eslicarbazepine showed an inducing effect on the metabolism of medicinal products that are mainly eliminated by metabolism through CYP3A4 (e.g. Simvastatin). 
Izkazalo se je, da ima eslikarbazepin in vivo spodbujevalni učinek na presnovo zdravil, ki se izločajo predvsem prek sistema CYP3A4 (npr. simvastatin).
After first opening, oral suspension may be used for up to 2 months Open date: ---/---/-- 
EXP Po prvem odprtju se lahko peroralna suspenzija uporablja do 2 mesece.
The steady state plasma concentrations are attained after 4 to 5 days of once daily dosing, consistent with an effective half-life in the order of 20-24 hours. 
Koncentracije v stanju dinamičnega ravnovesja so dosežene po 4 do 5 dneh odmerjanja enkrat na dan, kar je skladno z efektivnim razpolovnim časom 20-24 h. V študijah pri zdravih osebah je bil razpolovni čas eslikarbazepina
Children with ≥60 kg Children with 60 kg or more body weight should take the same dose as adults. 
Otroci s ≥ 60 kg Otroci s 60 kg telesne mase ali več jemljejo enak odmerek kot odrasli.
Zebinix may make you feel dizzy, drowsy and affect your vision, particularly at the beginning of treatment. 
Zaradi zdravila Zebinix ste lahko omotični ali dremavi in utegnete imeti motnje vida, zlasti na začetku zdravljenja.
Forty-two patients (50.6%) in the eslicarbazepine acetate group compared to 10 patients (25.0%) in the placebo group were responders (≥50% reduction of standardised seizure frequency), resulting in a significant difference (p=0.009). 
Dvainštirideset bolnikov (50,6 %) v skupini z eslikarbazepinacetatom v primerjavi z 10 bolniki (25,0 %) v skupini s placebom je bilo odzivnih (≥ 50-% zmanjšanje standardizirane pogostnosti napadov), kar je povzročilo značilno razliko (p = 0,009).